• +1-646-491-9876
    • +91-20-67278686

    Search

    Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2017

    Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689383
    • Category Healthcare
    • No. of Pages 57
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2017, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

    Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Prader-Willi Syndrome (PWS) - Overview
    Prader-Willi Syndrome (PWS) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Prader-Willi Syndrome (PWS) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development
    Alize Pharma SAS
    Essentialis Inc
    INSYS Therapeutics Inc
    LG Chem, Ltd.
    Saniona AB
    Prader-Willi Syndrome (PWS) - Drug Profiles
    (metoprolol + tesofensine) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZP-531 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BSN-175 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cannabidiol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    carbetocin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diazoxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diazoxide choline CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Eutropin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HM-04 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KAL-671 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    setmelanotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Glycogen Synthase for Prader-Willi Syndrome and Glycogen Storage Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Prader-Willi Syndrome (PWS) - Dormant Projects
    Prader-Willi Syndrome (PWS) - Discontinued Products
    Prader-Willi Syndrome (PWS) - Product Development Milestones
    Featured News & Press Releases
    Nov 07, 2016: Saniona Plans To Initiate Phase 2A Study In Prader-Willi In 2017
    Jul 20, 2016: Kalytera Therapeutics Presents New Data Demonstrating KAL671 Ability to Prevent Bone Loss in a Prader-Willi Syndrome Animal Model
    Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences
    Jul 05, 2016: Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference
    Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome
    Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome
    Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome
    Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies
    Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Prader-Willi Syndrome (PWS) - Pipeline by Alize Pharma SAS, H1 2017
    Prader-Willi Syndrome (PWS) - Pipeline by Essentialis Inc, H1 2017
    Prader-Willi Syndrome (PWS) - Pipeline by INSYS Therapeutics Inc, H1 2017
    Prader-Willi Syndrome (PWS) - Pipeline by LG Chem, Ltd., H1 2017
    Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H1 2017
    Prader-Willi Syndrome (PWS) - Dormant Projects, H1 2017
    Prader-Willi Syndrome (PWS) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Alize Pharma SAS
    Essentialis Inc
    INSYS Therapeutics Inc
    LG Chem, Ltd.
    Saniona AB

    Request for Sample

    Report Url https://www.reportsweb.com//prader-willi-syndrome-pws-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//prader-willi-syndrome-pws-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//prader-willi-syndrome-pws-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments